Dr. Pearlman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3 Parkcenter Dr.
Suite 100
Sacramento, CA 95825Phone+1 916-454-4861Fax+1 916-454-3603
Summary
- Dr. Joel Pearlman is an ophthalmologist in Sacramento, CA and is affiliated with multiple hospitals in the area, including Doctors Medical Center of Modesto, Mercy General Hospital, Sutter Medical Center, Sacramento, and Sutter Roseville Medical Center. He received his medical degree from Baylor College of Medicine and has been in practice 22 years. He specializes in retinal disease and is experienced in retina surgery, vitreoretinal disease, and uveitis and ocular immunology.
Education & Training
Johns Hopkins UniversityResidency, Ophthalmology, 1996 - 1999
Sinai Hospital of BaltimoreInternship, Internal Medicine, 1995 - 1996
Baylor College of MedicineClass of 1995
Certifications & Licensure
CA State Medical License 2002 - 2026
MD State Medical License 1999 - 2003- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD Start of enrollment: 2006 Apr 01
- Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD Start of enrollment: 2015 Jul 01
Publications & Presentations
PubMed
- Phase 1b Dose Escalation Study of Sozinibercept Inhibition of Vascular Endothelial Growth Factors C and D With Aflibercept for Diabetic Macular Edema.David S Boyer, Nathan C Steinle, Joel A Pearlman, Cameron M Stone, Courtney Crawford
Translational Vision Science & Technology. 2024-12-02 - 1 citationsSafety and Tolerability of Suprachoroidal Axitinib Injectable Suspension, for Neovascular Age-related Macular Degeneration; Phase I/IIa Open-Label, Dose-Escalation Trial.Mark R Barakat, David Brown, Allen Hu, Rahul N Khurana, Dennis Marcus
Ophthalmology Science. 2024-07-25 - 6 citationsRandomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.Anat Loewenstein, Norbert Czumbel, Jan Ernest, Jaroslava Dusová, Joel Pearlman
Ophthalmology. Retina. 2023-09-01
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
